### Edgar Filing: CATABASIS PHARMACEUTICALS INC - Form 4

CATABAS Form 4 August 05, 2	IS PHARMACE	UTICALS	INC						
Check th if no lon subject t Section Form 4 of Form 5 obligatio may con <i>See</i> Instr 1(b).	S SECURITIES AND EXCHANGE COM Washington, D.C. 20549 F CHANGES IN BENEFICIAL OWNER SECURITIES Section 16(a) of the Securities Exchange Ac Public Utility Holding Company Act of 193 of the Investment Company Act of 1940				WNERSHIP OF nge Act of 1934, of 1935 or Secti	N OMB Number: Expires: Estimated burden hor response.	rs per		
(Print or Type	Responses)								
(Last) C/O CATA PHARMAO KENDALL	, , ,	(Middle) IC., ONE	Symbol CATA PHAR [CATE 3. Date of	MACEUT ] of Earliest T Day/Year)	FICALS		5. Relationship Issuer (Ch X_ Director Officer (giv below)	eck all applicabl	
B14202 (Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
CAMBRID	GE, MA 02139							More than One R	
(City)	(State)	(Zip)	Tab	ole I - Non-l	Derivative	Securities A	cquired, Disposed	of, or Beneficia	ally Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	e 2A. Deem Execution any (Month/D	Date, if	3. 4. Securities TransactionAcquired (A) or Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5) (A) or Code V Amount (D) Prior		(A) or of (D) 4 and 5) (A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Reminder: Rej	port on a separate lin	e for each cl	lass of sec	urities bene	•	•	•		
							spond to the colle ained in this form		SEC 1474 (9-02)

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

number.

required to respond unless the form displays a currently valid OMB control

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number out Derivativ Securities Acquired (A) or Disposed or (D) (Instr. 3, 4, and 5)	e Expiration I (Month/Day	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (I	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 4.55	08/03/2016		А	6,500	<u>(1)</u>	08/02/2026	Common Stock	6,500	

### Edgar Filing: CATABASIS PHARMACEUTICALS INC - Form 4

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships				
FB	Director	10% Owner	Officer	Other	
ROSS MICHAEL JAY C/O CATABASIS PHARMACEUTICALS, INC. ONE KENDALL SQ, BLDG 1400E, STE B14202 CAMBRIDGE, MA 02139	Х				
Signatures					
/s/ Andreas Matthews, as attorney-in-fact for Michae Ross	uel Jay 08/05/2016				
<b>**</b> Signature of Reporting Person		D	ate		

# \*\*Signature of Reporting Person

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This option was granted on August 3, 2016 and is scheduled to vest in full on June 15, 2017.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.